Development of resistance to biologic therapies with reference to IFN-β

Rheumatology

Volumn 51, Issue 4, 2012, Pages 590-599

  Farrell, Rachel A ^a,b,c   Marta, Monica ^c   Gaeguta, Adriana J ^c   Souslova, Veronika ^c   Giovannoni, Gavin ^c   Creeke, Paul I ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti drug antibodies; Biotherapeutic; Immunogenicity; Interferon ; Multiple sclerosis; Neutralizing antibodies; Tolerance

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; DRUG ANTIBODY; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN; NEUTRALIZING ANTIBODY;

ANEMIA; ANTIBODY DETECTION; CELL ASSAY; CYTOPATHOGENIC EFFECT; DISEASE COURSE; DRUG INDICATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RESISTANCE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLU LIKE SYNDROME; GENE EXPRESSION REGULATION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INJECTION SITE REACTION; LEUKOPENIA; LIVER FUNCTION TEST; MULTIPLE SCLEROSIS; MYALGIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANTIBODY FORMATION; DRUG RESISTANCE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 84857594108     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker445     Document Type: Review

References (100)

1. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16(Suppl. 3):155-65.
2. Steenholdt C, Svenson M, Bendtzen K et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:51-8.
3. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011;100: 354-87.
4. Buck D, Cepok S, Hoffmann S et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011;68: 480-7.
5. Weber F, Cepok S, Wolf C et al. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-beta therapy in multiple sclerosis patients. Pharmacogenomics J 2011, Advance Access published 19 April 2011, doi:10.1038/ tpj.2011.14.
6. Enevold C, Oturai AB, Sorensen PS et al. Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. Mult Scler 2010;16: 942-9.
7. Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-24.
8. Bendtzen K, Geborek P, Svenson M et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9.
9. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
10. Singh SK, Afonina N, Awwad M et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 2010;99:3302-21.
11. Hartung HP, Polman C, Bertolotto A et al. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J Neurol 2007;254:827-37.
12. Polman CH, Bertolotto A, Deisenhammer F et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9:740-50.
13. Meager A, Dolman C, Dilger P et al. An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J Interferon Cytokine Res 2011;31:383-92.
14. Conradt HS, Egge H, Peter-Katalinic J et al. Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. J Biol Chem 1987;262:14600-5.
15. Runkel L, Meier W, Pepinsky RB et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 1998;15:641-9.
16. Meager A, Dolman C, Dilger P et al. An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J Interferon Cytokine Res 2011;31:383-92.
17. Lin L. Betaseron. Dev Biol Stand 1998;96:97-104.
18. Kumar S, Singh SK, Wang X et al. Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions. Pharm Res 2011;28:949-61.
19. Giovannoni G, Barbarash O, Casset-Semanaz F et al. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther 2007;29:1128-45.
20. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004;101(Suppl. 2):14599-606.
21. Kutzelnigg A, Faber-Rod JC, Bauer J et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 2007;17:38-44.
22. Kutzelnigg A, Lucchinetti CF, Stadelmann C et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-12.
23. Gilmore CP, Bo L, Owens T et al. Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. Brain Pathol 2006;16:202-8.
24. Peterson JW, Bo L, Mork S et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
25. Trapp BD, Peterson J, Ransohoff RM et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.
26. Mix E, Meyer-Rienecker H, Zettl UK. Animal models of multiple sclerosis for the development and validation of novel therapies-potential and limitations. J Neurol 2008; 255(Suppl. 6):7-14.
27. van Sechel AC, Bajramovic JJ, van Stipdonk MJ et al. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 1999;162: 129-35.
28. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
29. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008;21:172-88.
30. Borden EC, Sen GC, Uze G et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90.
31. Hecker M, Goertsches RH, Fatum C et al. Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment. Pharmacogenomics J 2010, Advance Access published 19 October 2010, doi:10.1038/tpj.2010.77.
32. Goertsches RH, Hecker M, Koczan D et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010;11: 147-61.
33. Serrano-Fernandez P, Moller S, Goertsches R et al. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity 2010;43:172-8.
34. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009;73:372-7.
35. Hussien Y, Sanna A, Soderstrom M et al. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001;121:102-10.
36. Yong VW, Chabot S, Stuve O et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-9.
37. Sharief MK, Semra YK, Seidi OA et al. Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol 2001;120:199-207.
38. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 2002;59:802-8.
39. Leppert D, Waubant E, Burk MR et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-52.
40. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 655-61.
41. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
42. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
43. O'Connor P. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin Ther 2003;25:2865-74.
44. Koch MW, Mostert JP, de Vries JJ et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2007;68:1163-4.
45. Kappos L, Freedman MS, Polman CH et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97.
46. van Baarsen LG, Vosslamber S, Tijssen M et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 2008;3: e1927.
47. Munschauer FE 3rd, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883-93.
48. Platanias LC. Mechanisms of type-I- and type-IIinterferon-mediated signalling. Nat Rev Immunol 2005;5: 375-86.
49. Joshi S, Kaur S, Kroczynska B et al. Mechanisms of mRNA translation of interferon stimulated genes. Cytokine 2010; 52:123-7.
50. Ross C, Clemmesen KM, Svenson M et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48: 706-12.
51. Malucchi S, Sala A, Gilli F et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004;62:2031-7.
52. Bertolotto A, Gilli F, Sala A et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003;60:634-9.
53. Cook SD, Quinless JR, Jotkowitz A et al. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 2001;57: 1080-4.
54. Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59: 1496-506.
55. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-94.
56. Kappos L, Clanet M, Sandberg-Wollheim M et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005;65:40-7.
57. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55.
58. Deisenhammer F, Mayringer I, Harvey J et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 2000;54:2055-60.
59. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003;61(9 Suppl. 5):S24-6.
60. Pachner AR, Warth JD, Pace A et al. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology 2009;73:1493-500.
61. Pachner A, Narayan K, Price N et al. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003;7:17-25.
62. Rudick RA, Simonian NA, Alam JA et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50:1266-72.
63. Scagnolari C, Duda P, Bagnato F et al. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol 2007;254: 597-604.
64. Wandinger KP, Lunemann JD, Wengert O et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003;361:2036-43.
65. Gilli F, Marnetto F, Caldano M et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 2006;12:47-57.
66. Gilli F, Marnetto F, Caldano M et al. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 2005;158: 195-203.
67. Deisenhammer F, Reindl M, Harvey J et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-43.
68. Vallittu AM, Halminen M, Peltoniemi J et al. Neutralizing antibodies reduce MxA protein induction in interferonbeta-1a-treated MS patients. Neurology 2002;58: 1786-90.
69. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 2008;79:57-62.
70. Sorensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12: 817-27.
71. Gneiss C, Brugger M, Millonig A et al. Comparative study of four different assays for the detection of binding antibodies against interferon-beta. Mult Scler 2008;14:830-6.
72. WHO. WHO Expert Committee on Biological Standardization, Thirty-fifth Report. WHO Technical Report Series. Geneva: WHO, 1985.
73. Grossberg SE, Kawade Y, Kohase M et al. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001; 21:729-42.
74. Grossberg SE, Kawade Y, Kohase M et al. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001;21: 743-55.
75. Bertolotto A, Sala A, Caldano M et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 2007;321:19-31.
76. Malucchi S, Gilli F, Caldano M et al. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol 2011;258: 895-903.
77. Farrell R, Espasandin M, Lakdawala N et al. Incorporation of an interferon-b neutralizing antibody assay into routine clinical practice. Mult Scler 2011, Advance Access published 17 June 2011, doi:10.1177/1352458511412654.
78. Farrell R, Kapoor R, Leary S et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler 2008;14:212-8.
79. Lam R, Farrell R, Aziz T et al. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods 2008;336:113-8.
80. Uze G, Di Marco S, Mouchel-Vielh E et al. Domains of interaction between alpha interferon and its receptor components. J Mol Biol 1994;243:245-57.
81. Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17.
82. Hartung HP, Munschauer FE 3rd. Assessment and management of neutralizing antibodies in patients with multiple sclerosis. J Neurol 2004;251(Suppl. 2):II40-2.
83. Farrell RA, Giovannoni G. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler 2007;13:567-77.
84. Goodin DS, Frohman EM, Hurwitz B et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68:977-84.
85. Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010;5:113-28.
86. Knop K, Hoogenboom R, Fischer D et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010;49: 6288-308.
87. Alconcel SNS, Baas AS, Maynard HD. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym Chem 2011;2:1442-8.
88. Sun B, Kulis MD, Young SP et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther 2010;18:353-60.
89. Douillard-Guilloux G, Richard E, Batista L et al. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease. J Gene Med 2009;11:279-87.
90. Joseph A, Munroe K, Housman M et al. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 2008;152:138-46.
91. Hu C, Cela RG, Suzuki M et al. Neonatal helperdependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proc Natl Acad Sci USA 2011;108:2082-7.
92. Zhang AH, Skupsky J, Scott DW. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood 2011;117:2223-6.
93. Finn JD, Ozelo MC, Sabatino DE et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 2010;116:5842-8.
94. Astermark J. Immune tolerance induction in patients with hemophilia A. Thromb Res 2011;127(Suppl. 1):S6-9.
95. Ter Avest PC, Fischer K, Gouw SC et al. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia 2010;16:71-9.
96. Stiefel M, Pinkwart C, Haase R et al. [Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin]. Hamostaseologie 2010;30(Suppl. 1): S119-21.
97. Pryce G, O'Neill JK, Croxford JL et al. Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J Neuroimmunol 2005;165: 41-52.
98. Millonig A, Rudzki D, Holzl M et al. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. Mult Scler 2009;15:977-83.
99. Camacho-Halili M, George R, Gottesman M et al. An approach to natalizumab hypersensitivity: a case series of induction of tolerance. Mult Scler 2011;17:250-3.
100. Somerfield J, Hill-Cawthorne GA, Lin A et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 2010;185:763-8.